MedTrace Logo

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

NCT03582124 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-10

No results posted yet for this study

Summary

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Conditions

  • Lung Carcinoma
  • Metastatic Malignant Neoplasm in the Lung
  • Stage IV Lung Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8

Interventions

PROCEDURE

Near-Infrared Fluorescence Imaging

Undergo imaging

DRUG

Panitumumab-IRDye800

Given IV

OTHER

Pharmacokinetic Study

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Sponsors & Collaborators

Principal Investigators

  • Natalie Lui · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03582124 on ClinicalTrials.gov